Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FitFlow vs June Health

FitFlow
Graded #155

Higher grade

vs+4.799999999999997
June Health
Graded #261

Lower grade

The verdict

FitFlow takes it — 67.8/100 to 63/100.

FitFlow grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FitFlow (FitFlow Health) is a 100% online compounded telehealth platform for GLP-1 weight loss - compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueJune Health +3
58
61
Dose & formulationFitFlow +2
77
75
Clinical oversightFitFlow +26
85
59
Labs & monitoringFitFlow +4
55
51
FulfillmentFitFlow +7
81
74
Contract termsJune Health +18
37
55
FitFlow · left barJune Health · right bar

The numbers

MetricFitFlowJune Health
WeighScore67.8/10063/100
GradeCC
Scorecard rank#155#261
Semaglutide$175/mo (compounded)$179/mo (starting dose, compounded)
Tirzepatide$235/mo (compounded)$179/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
FitFlow

Graded #155 · C

Strengths

  • Compounded semaglutide (=Wegovy) and tirzepatide (=Mounjaro); month-to-month from $175/$235, or as low as $99/$125 on annual prepay
  • 100% online 4-step process; board-certified provider review in 24-48 hours, with unlimited messaging and dose adjustments
  • Free nationwide shipping (discreet, 5-7 days) from US-licensed compounding pharmacies
  • FSA/HSA eligible with financing (Affirm, Klarna, Afterpay); month-to-month or prepay plans, cancel anytime
  • Transparent 'no hidden fees' pricing; 6,000+ members; same-platform add-ons (NAD+, sermorelin, MIC+B12, glutathione, hair, sexual health)

Where it loses points

  • Headline '$99/$125 a month' requires a full year prepaid upfront ($1,188 / $1,500); true month-to-month is $175 / $235
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('US-licensed / FDA-regulated pharmacies' only)
  • State-availability list is not published (free nationwide shipping advertised, but no explicit state list)
  • No LegitScript certification displayed
June Health

Graded #261 · C

Strengths

  • Offers both injectable and oral compounded semaglutide and tirzepatide
  • Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
  • Full per-dose price list published on-site with no signup required to view it
  • Provider consult ('licensed clinician evaluation') is bundled into the displayed price
  • Free discreet shipping advertised with 2-3 day delivery

Where it loses points

  • No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
  • No LegitScript seal or other pharmacy-verification badge found anywhere on the site
  • Legal entity, prescribing medical group, and compounding pharmacy partner are not named
  • Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
  • Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard